YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Biogen Inc. –4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of sta…
–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of car…
BEDFORD, Mass., September 02, 2026--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investiga…
–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen– –Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductio…
Image source: The Motley Fool. DATE Monday, Aug. 3, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Financial Officer - Thomas LeggettChief Executive Officer - Ian SmithChief Medical Officer - Barry TichoChief Patient Officer - Jason Hoitt Ne…
Earnings Call Insights: Stoke Therapeutics (STOK) Q2 2026 MANAGEMENT VIEW * "Starting with our Phase III EMPEROR study, the recent completion of enrollment of 162 patients in just 10 months speaks to the awareness and enthusiasm of zorevun…
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.4 per share a year ago. These figures are adjusted for non-recurring it…
Ionis Pharmaceuticals IONS announced that it has dosed the first patient in the phase I/II ASCEND study, which is evaluating its investigational RNA-targeted medicine, ION337, for treating patients with Dravet syndrome, a rare and severe n…
The biotech industry has navigated the uncertain macroeconomic environment effectively so far this year. Upbeat first-quarter results, new drug approvals and positive clinical and pipeline developments have continued to drive momentum desp…
Stoke Therapeutics, Inc. (NASDAQ:STOK) is one of the 10 Best Russell 2000 Stocks to Invest In According to Hedge Funds. On May 7, Stoke Therapeutics, Inc. (NASDAQ:STOK) reported Q1 results and business updates. The company stated that four…
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.5 per share a year ago. These figures are adjusted for non-recurring it…
Zealand Pharma Eric RojasVP, Head of Investor Relations·GlobeNewswire Inc. Press release – No. 7 / 2026 Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations Bringing significant experience from Vertex Pharmac…
VANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one of them carried mid or late stage clinical…
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. At the beginning of 2025, Biogen CEO Christopher Viehbacher tried to temper expectations arou…
Key Points The chair of Stoke Therapeutics disclosed selling 4,355 shares for roughly $174,000 at around $40.00 per share on March 10, 2026. The sale represented 12.20% of Tzianabos' direct Common Stock holdings, reducing direct ownership…
Barry Ticho, chief medical officer of Stoke Therapeutics(NASDAQ:STOK), reported the direct sale of 14,311 shares of Common Stock for a transaction value of approximately $457,000 between March 17, 2026 and March 19, 2026, as disclosed in t…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Biogen (NasdaqGS:BIIB) reported one year results for salanersen in…
Vertex Pharmaceuticals (VRTX) shares soared 8.3% in the last trading session to close at $499.17. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.1% loss over…
March S&P 500 E-Mini futures (ESH26) are trending down -0.53% this morning as Treasury yields continued to rise after another surge in oil prices stoked concerns that the Middle East conflict would drive inflation higher. The 10-year T-not…
In recent days, Stoke Therapeutics and Biogen reported that data on the investigational Dravet syndrome medicine zorevunersen were published in The New England Journal of Medicine, alongside Stoke’s updated Phase 3 EMPEROR timeline and pla…
(RTTNews) - Stoke Therapeutics (STOK) and Biogen (BIIB) announced the publication of data from studies of the investigational medicine zorevunersen. This includes results from two completed Phase 1/2a and ongoing open-label extension studi…
Biogen Inc. –Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support ongoing global Phase 3 EMPEROR…
–Results show that targeting the underlying cause of Dravet syndrome with zorevunersen may improve outcomes for people with this rare, devastating genetic neurodevelopmental disease– –Data support ongoing global Phase 3 EMPEROR study– BEDF…
Two eyedrops stocks are forming cup bases on their charts and one has earnings coming up. A data center play is in a cup base buy zone. Continue Reading
Rare disease treatment developer Stoke Therapeutics is Monday's IBD 50 Growth Stocks To Watch pick as the biotech name hit a buy point. Its shares had climbed sharply despite the broader market sell-off, but the shares lost some of their m…
On February 17, 2026, Redmile Group disclosed a buy of 4,415,514 Nurix Therapeutics(NASDAQ:NRIX) shares, an estimated $63.43 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commission…
On February 17, 2026, Redmile Group disclosed a buy of 695,000 shares of Immunome(NASDAQ:IMNM), an estimated $12.20 million trade based on quarterly average pricing. What happened According to a February 17, 2026, SEC filing, Redmile Group…
Redmile Group disclosed a significant reduction in its Zymeworks(NASDAQ:ZYME) position in a February 17, 2026, SEC filing, selling an estimated $70.10 million in shares based on quarterly average pricing. What happened According to a Febru…
Redmile Group reported a purchase of 16,317 shares of Krystal Biotech(NASDAQ:KRYS) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.43 million based on quarterly average pricing. What happened According to a…
Redmile Group disclosed a buy of 1,316,390 shares of Scholar Rock Holding Corporation(NASDAQ:SRRK) in a February 17, 2026, SEC filing, with the estimated transaction value at $49.37 million based on quarterly average pricing. What happened…
As February 2026 begins, the U.S. stock market has seen a robust start with major indices like the Dow Jones Industrial Average and S&P 500 showing significant gains, reflecting positive investor sentiment despite recent economic uncertain…
New Headquarters Will Support Company's Work to Deliver zorevunersen, a Potential Disease-Modifying Medicine, to Patients with Dravet Syndrome and Expansion of Research Efforts Lease is One of the Largest in Greater Boston Life Sciences Ov…
As the U.S. market navigates a landscape marked by fluctuating indices and inflation data that aligns with expectations, investors are keenly assessing the implications for high-growth sectors like technology. In this environment, identify…
Health care stocks were mixed late Monday afternoon, with the NYSE Health Care Index up 0.1% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
— Company now expects to complete enrollment of 150 patients in Q2 2026, with a Phase 3 data readout in mid-2027; Rolling NDA submission planned to initiate in first half 2027— — Discussions with FDA ongoing following recent multidisciplin…
BEDFORD, Mass., January 06, 2026--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigati…